Immunoprofiling of Adult-Derived Human Liver Stem/Progenitor Cells: Impact of Hepatogenic Differentiation and Inflammation

Hoda El-Kehdy,1 Camillo Sargiacomo,1 Mohammad Fayyad-Kazan,2 Hussein Fayyad-Kazan,3 Catherine Lombard,1 Laurence Lagneaux,4 Etienne Sokal,1 Mehdi Najar,4 and Mustapha Najimi1

1Institut de Recherche Expérimentale and Clinique (IREC), Laboratory of Pediatric Hepatology and Cell Therapy, Université Catholique de Louvain, 1200 Brussels, Belgium
2Institut de Biologie et de Médecine Moléculaires, Université Libre de Bruxelles, 6041 Gosselies, Belgium
3Laboratory of Cancer Biology and Molecular Immunology, Faculty of Sciences I, Lebanese University, Beirut, Lebanon
4Laboratory of Clinical Cell Therapy, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium

Correspondence should be addressed to Mustapha Najimi; mustapha.najimi@uclouvain.be

Received 28 September 2016; Revised 15 February 2017; Accepted 2 March 2017; Published 11 April 2017

Academic Editor: Eva Mezey

Copyright © 2017 Hoda El-Kehdy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Adult-derived human liver stem/progenitor cells (ADHLSCs) are, nowadays, developed as therapeutic medicinal product for the treatment of liver defects. In this study, the impact of hepatogenic differentiation and inflammation priming on the ADHLSCs’ immune profile was assessed in vitro and compared to that of mature hepatocytes. The constitutive immunological profile of ADHLSCs was greatly different from that of hepatocytes. Differences in the expression of the stromal markers CD90 and CD105, adhesion molecules CD44 and CD49e, immunoregulatory molecules CD73 and HO-1, and NK ligands CD112 and CD155 were noted. While they globally preserved their immunological profile in comparison to undifferentiated counterparts, differentiated ADHLSCs showed a significant downregulation of CD200 expression as in hepatocytes. This was mainly induced by signals issued from EGF and OSM. On the other hand, the impact of inflammation was quite similar for all studied cell populations with an increased expression level of CD54 and CD106 and induction of that of CD40 and CD274. In conclusion, our immune profiling study suggests CD200 as a key factor in regulating the immunobiology of differentiated ADHLSCs. A better understanding of the molecular and physiological events related to such marker could help in designing the optimal conditions for an efficient therapeutic use of ADHLSCs.

1. Introduction

To date, cell therapy for metabolic liver diseases and hepatic injuries mainly relies on the use of various types of cells including hepatocytes, liver sinusoidal endothelial cells, mesenchymal stem cells (MSCs), endothelial progenitor cells, and macrophages [1]. However, several limitations and problems are associated with these cells that will finally have a critical impact on the efficiency of liver cell therapy [1]. Adult-derived human liver stem/progenitor cells (ADHLSCs) are obtained, in vitro, after primary culture of healthy adult human liver parenchymal cell fraction [2]. These cells exhibit a fibroblastic morphology and a hepatomesenchymal phenotype [2]. Even though considered as MSC-like, much less is known about ADHLSCs in comparison to the classical MSCs. It is reported that ADHLSCs, in their basal state, demonstrate distinct expression and secretion profiles [3, 4]. When exposed to in vitro hepatogenic differentiation, ADHLSCs are capable to differentiate, either in vitro or in vivo, into hepatocyte-like cells [4]. Recently, upon characterizing the immunological profile of ADHLSCs, our group showed that besides their potency in suppressing T cell proliferation, ADHLSCs are nonimmunogenic since they are negative for HLA-DR as well as for costimulatory molecule expression [5]. Altogether, their self-renewal potential,
ability to acquire hepatocyte features, and their hypoimmunogenicity highlight ADHLSCs as a potential alternative cell source for liver cell transplantation. However, achieving these goals involves addressing different aspects related to their safety and efficacy. For instance, tracking the changes of ADHLSCs’ immunological profile following hepatogenic differentiation and after exposure to inflammation is missing.

Accordingly, the current work was designed to learn more about the ADHLSC immune profile modulation after in vitro hepatogenic differentiation and in an inflammatory environment. Flow cytometry analysis demonstrated the dissimilarity between hepatocytes and undifferentiated ADHLSCs as shown by the expression of stromal markers CD90 and CD105, adhesion molecules CD44 and CD49e, immune regulatory molecules CD73 and HO-1, and NK ligands CD112 and CD105. We also confirmed that differentiated ADHLSCs do not acquire a complete and similar hepatocyte immune phenotype but rather maintain a profile comparable to that of undifferentiated cells. However, a specific and major downregulation of CD200 expression was highlighted to reach basal levels as those exhibited by hepatocytes. The impact of inflammation was quite similar for all studied cell populations with an increase in the expression level of CD54 and CD106 and induction of that of CD40 and CD274.

Downregulation of CD200 expression occurred early during the in vitro hepatocytic differentiation process and is modulated by the epidermal growth factor (EGF). Oncostatin M is also inhibiting CD200 mRNA expression at the late maturation phase of the hepatogenic differentiation process. Besides identifying CD200 expression level as an important marker to distinguish hepatic differentiated versus undifferentiated ADHLSCs, our observations suggest a potential role for CD200 in regulating the immunobiology of ADHLSCs. The loss of CD200 might have critical repercussions on the differentiation of ADHLSCs and specifically for liver immunology.

2. Materials and Methods

2.1. Isolation and Culture of Hepatocytes and ADHLSC. The present study was accepted by the institution ethical review board for the use of human-derived tissue, under appropriate informed consent of tissue donors. An agreement from the Belgian Ministry of Health was delivered for hepatocytes and hepatic stem cell isolation and banking.

Liver cell suspensions were recovered after a two-step collagenase perfusion technique of livers from healthy cadaveric donors. Following filtration and low-speed centrifugation, the parenchymal fraction, predominantly constituted by hepatocytes, was recovered and seeded as primary cultures. ADHLSCs were then obtained as previously described (Najimi et al. [2]). The cells were cultured using DMEM containing 4.5 g/l glucose (Life Technologies) supplemented with 10% fetal calf serum (FCS) (Life Technologies) and 1% penicillin/streptomycin (Life Technologies), at 37°C in a fully humidified atmosphere (5% CO2). When reaching 80% confluence, cells were lifted with 0.05% Trypsin-EDTA (Life Technologies) and seeded at a density of 5000 cells/cm². The viability of recovered cells was evaluated using Trypan blue exclusion assay at each passage.

2.2. Hepatogenic Differentiation of ADHLSC. After seeding at 10⁴ cells/cm² in six-well plates coated with rat tail collagen type I, ADHLSCs were maintained in expansion medium for 48h. Thereafter, cells were sequentially incubated with hepatogenic differentiation cocktail containing specific growth factors and cytokines as previously described (Najimi et al. [2]). Except for step 1 (one medium change), the differentiation medium was changed each 3 days and the cells were microscopically followed at a regular basis. At the end of the maturation step, cells were harvested for analyses to appreciate the level of their phenotypic and functional differentiation. Control undifferentiated cells were kept during the whole process of differentiation in IMDM medium supplemented with 1% FCS.

2.3. Inflammation Priming. Adherent cells were primed overnight using a cocktail of proinflammatory cytokines: 25 ng/ml IL-1β (Peprotech, Rocky Hill, NJ, USA), 10³ U/ml IFN-γ, 50 ng/ml TNF-α, and 3x10⁵ U/ml IFN-α (all from ProSpec Inc., Rehovot, Israel).

2.4. Flow Cytometry. A panel of conjugated monoclonal antibodies (Table 1) was used to assess the phenotype of the cells studied under different culture conditions. After labelling, acquired results were analyzed by using a MACSQuant analyzer (Miltenyi Biotec) [5].

2.5. RT-qPCR. ADHLSCs’ total RNA was extracted using TruPure Isolation Reagent (Roche, Belgium). First-strand cDNA was synthesized using high-capacity cDNA reverse transcription kit according to manufacturer’s instructions (Applied Biosystems) and subsequently diluted with nuclease-free water (Invitrogen) to 10 ng/μl cDNA. RT-PCR amplification mixtures (25 μl) containing 25 ng template cDNA, Master Mix buffer (12.5 μl) (Applied Biosystems), and the corresponding TaqMan assay were run in duplicate and performed on StepOnePlus real-time PCR machine (Applied Biosystems). The cycling conditions comprised 10 min polymerase activation at 95°C and 40 cycles at 95°C for 15 s and 60°C for 1 min. Relative quantification was normalized against the house-keeping gene PPIA. The Applied Biosystems assays used for the current study are CD200 (Hs01033303_m1) and cyclophilin A (PPIA) (Hs99999904_m1).

2.6. Immunofluorescence. ADHLSCs from 3 different donors at passage 6 grown on glass labtek were fixed with 4% paraformaldehyde (Sigma) for 15 min at room temperature. Non-specific immunostaining was prevented by 30 min incubation in PBS containing 3% (v/v) bovine serum albumin (BSA). Cells were incubated for 1 hour with polyclonal goat anti-CD200 primary antibody (AF2724 R&D systems) at room temperature. After washing with PBS, ADHLSCs were incubated for 30 min with donkey anti-goat secondary antibody (A11055, Life Technologies) at room temperature. Nuclei were stained for 5 min with DAPI (Life Technologies). Slides were mounted in fluoromount medium (Sigma).
Table 1: Conjugated monoclonal antibodies used for flow cytometry analysis.

| Primary antibody | Order ID | Species | Dilution | Source |
|------------------|----------|---------|----------|--------|
| **Endothelial, stromal, and embryonic markers** | | | | |
| Anti-CD34-PE5 | 555823 | Mouse | 1/20 | BD |
| Anti-CD90-PE | FAB2067P | Mouse | 1/20 | R&D |
| Anti-CD105-FITC | 326040 | Mouse | 1/20 | AC |
| Anti-SSEA4-PE | FAB1435P | Mouse | 1/20 | R&D |
| **Receptors** | | | | |
| Anti-CD45-PC7 | 557748 | Mouse | 1/20 | BD |
| Anti-CD95-FITC | 130092415 | Mouse | 1/20 | MB |
| Anti-CD184-PE | 555974 | Mouse | 1/20 | BD |
| Anti-CD200R-PE | 329306 | Mouse | 1/20 | BL |
| Anti-CD200-APC | 329208 | Mouse | 1/20 | BL |
| Anti-CD73-PE344003 | Mouse | 1/20 | BD |
| Anti-CD39-FITC | 328205 | Mouse | 1/20 | BL |
| Anti-CD62e- | | | | |
| Anti-CD58-FITC | 555920 | Mouse | 1/20 | BD |
| **Human leukocyte antigens** | | | | |
| Anti-HLA-ABC-PE-Cy5 | 15998342 | Mouse | 1/20 | EB |
| Anti-HLA-DR-PerCP | 347402 | Mouse | 1/20 | BD |
| Anti-HLA-G-PE | 1P292C100 | Mouse | 1/20 | ExBIO |
| **Costimulatory molecules** | | | | |
| Anti-CD27-APC-Cy7 | 302815 | Mouse | 1/20 | BL |
| Anti-CD40-PE | 130094135 | Mouse | 1/20 | MB |
| Anti-CD70-PE | 355104 | Mouse | 1/20 | BL |
| Anti-CD80-PE | 11080942 | Mouse | 1/20 | EB |
| Anti-CD95-PE | 130094876 | Mouse | 1/20 | MB |
| Anti-CD200R-PE | 350066 | Mouse | 1/20 | BL |
| Anti-CD154-PE-Cy5 | 310808 | Mouse | 1/20 | BL |
| Anti-CD155-PE | 326308 | Mouse | 1/20 | BL |
| **Cell adhesion molecules** | | | | |
| Anti-CD29-PE-Cy5 | 559882 | Mouse | 1/20 | BD |
| Anti-CD31-PE | 130092653 | Mouse | 1/20 | MB |
| Anti-CD44-FITC | 130095195 | Mouse | 1/20 | MB |
| Anti-CD54-PE | 555517 | Mouse | 1/20 | BD |
| Anti-CD58-FITC | 555920 | Mouse | 1/20 | BD |
| **Immunoregulatory molecules** | | | | |
| Anti-CD39-FITC | 328205 | Mouse | 1/20 | BL |
| Anti-CD33-PE | 344003 | Mouse | 1/20 | BD |
| Anti-CD200-APC | 329208 | Mouse | 1/20 | BL |
| Anti-CD274-PE | 557924 | Mouse | 1/20 | BD |
| Anti-HO-1-PE | ADI-Osa-111 | Mouse | 1/20 | ELS |

Table 1: Continued.

| Primary antibody | Order ID | Species | Dilution | Source |
|------------------|----------|---------|----------|--------|
| **NK ligands** | | | | |
| Anti-CD112-PE | 337410 | Mouse | 1/20 | BL |
| Anti-CD155-PE | 337508 | Mouse | 1/20 | BL |
| Anti-ULBP-3-PE | FAB1517P | Mouse | 1/20 | R&D |

Fluorescence was assessed using Imager A1 fluorescent microscope (Carl Zeiss), and digital images were acquired using AxioVision Software.

2.7. Western Blot Analysis. Total protein lysates were obtained by dissolving ADHLSC pellets in RIPA buffer [50 mM Tris base, pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, with protein inhibitors cocktail without EDTA (Roche)]. Protein samples were sonicated shortly and incubated for 30 minutes at 4°C prior to sample clarification by centrifugation (15 min maximum speed). Subsequently, sample supernatants were collected and a total protein quantification was performed (BCA quantification kit, ThermoFisher). Twenty μg of total protein extracts were dissolved in loading buffer [Tris-HCl (pH 6.8), glycerol, SDS, DTT, and bromophenol blue], denatured at 95°C for 5 minutes and loaded on a 10% Tris-glycine SDS-PAGE gel for protein separation and transferred overnight at 4°C onto PVDF membranes. Membranes were incubated with 5% BSA blocking solution for 90 min at room temperature. CD200 antibody [0.1 μg/ml] was incubated 90 min at room temperature, and the membranes were thoroughly washed 3× with PBS-T, incubated with fluorescently labelled secondary antibody (Biotium) for 40 min at room temperature, and detected by Li-cor scanner (Odyssey). Quantification analysis was performed by Image Studio Lite Software (Odyssey).

2.8. Construction of CD200 Protein-Protein Interaction (PPI) Network. We have used STRING database v10 (Search Tool for the Retrieval of Interacting Genes, available at http://string-db.org) [6] with CD200 as seed for construction of the protein-protein interaction (PPI) network.

2.9. Statistical Analyses. Results are expressed as mean ± standard error of the mean (SEM). Analyses were done in the GraphPad Prism software program (San Diego, California, USA). Statistical differences were determined by Student’s t-test for two groups’ comparison or by one-way ANOVA followed by the Tukey post hoc test for multiple comparisons between more than two groups. Differences were considered significant when p values are *p < 0.05, **p < 0.01, and ***p < 0.001.

3. Results

3.1. Flow Cytometry Characterization of ADHLSCs’ Immunological Profile after Hepatogenic Differentiation and Inflammation Priming. Flow cytometry analysis was initially carried out to determine the immunologic profile of ADHLSCs under low proliferation conditions and to characterize the impact of hepatogenic differentiation. The quality
Endothelial, stromal, and embryonic markers

(a)

Immunoregulatory molecules

(b)

Nk ligands

(c)

Figure 1: Continued.
of hepatogenic differentiation is systematically evaluated at the morphological, expression, and function levels (see Supplementary Figure 1 available online at https://doi.org/10.1155/2017/2679518). The influence of inflammation priming on such profile was also appreciated. Hepatocytes previously isolated from the same donors as ADHLSC were used for comparison as the golden standard reference for all these experimental conditions. The representative FACS histograms (Figure 1) and the related immunopositivity percentages (Table 2) reveal that ADHLSC express a plethora of molecules belonging to several distinct immunological families. Such independent analysis confirmed the mesenchymal profile of ADHLSC and its maintenance in low proliferating and differentiation conditions. Indeed, CD90 was highly and comparably expressed in undifferentiated ADHLSCs (82 ± 3.24%), inflammation-primed undifferentiated ADHLSCs (84 ± 2.52%), differentiated ADHLSC (75,20 ± 7.80%), and inflammation-primed hepatic differentiated ADHLSCs (78,50 ± 8.36%). CD105 expression level exhibited by undifferentiated ADHLSCs (31,83 ± 3.63%) was not significantly changed following inflammation priming (26 ± 2.63%) or after differentiation (29,45 ± 3.46%). Inflammation priming did not
| Receptors | CD45 | CD95 | CD184 | CD200R | CD210 | CD271 | CD229 |
|-----------|------|------|-------|--------|-------|-------|-------|
|           | 0.78 ± 0.23 | 2.45 ± 0.58 | 1.53 ± 0.55 | 1.02 ± 0.27 | 0.73 ± 0.19 | 2.18 ± 0.79 | 0.66 ± 0.17 |
|           | 1.29 ± 0.46  | 6.80 ± 1.94  | 2.06 ± 0.68  | 1.23 ± 0.12  | 1.6 ± 0.10  | 2.20 ± 0.34 | 0.53 ± 0.13 |
|           | 1.38 ± 0.60  | 3.25 ± 1.14  | 1.13 ± 0.18  | 0.79 ± 0.08  | 1.23 ± 0.13 | 2.33 ± 0.61 | 0.34 ± 0.09  |
|           | 0.71 ± 0.18  | 7.34 ± 1.92  | 1.06 ± 0.20  | 1.13 ± 0.33  | 1.30 ± 0.27 | 2.80 ± 0.60 | 0.47 ± 0.14  |
|           | 0.12 ± 0.08  | 0.20 ± 0.17  | 0.49 ± 0.23  | 0.32 ± 0.08  | 0.30 ± 0.18 | 0.42 ± 0.18 | 0.28 ± 0.08  |
|           | 2.08 ± 1.69  | 2 ± 0.86     | 0.73 ± 0.15  | 0.69 ± 0.29  | 0.66 ± 0.24 | 1.36 ± 0.72 | 0.25 ± 0.03  |

**Human leukocyte antigens**

| HLA-ABC | 92.83 ± 2.61 | 93.9 ± 2.88 | 96.16 ± 1.47 | 98.2 ± 0.34 | 89 ± 2.97 | 88 ± 5.02 |
| HLA-DR  | 0.78 ± 0.28  | 0.66 ± 0.23  | 0.6 ± 0.33   | 0.4 ± 0.15  | 1.5 ± 0.3  | 1.52 ± 1.49 |
| HLA-G   | 2.43 ± 1.13  | 1.62 ± 0.37  | 1.57 ± 0.28  | 1.58 ± 0.6   | 0.29 ± 0.16 | 0.47 ± 0.13 |

**Costimulatory molecules**

| CD27    | 0.27 ± 0.12  | 0.57 ± 0.20  | 1.06 ± 0.34  | 0.3 ± 0.12   | 0.36 ± 0.1  | 0.5 ± 0.07  |
| CD40    | 8.33 ± 0.88  | 70 ± 5.70    | 9.33 ± 0.84  | 68.6 ± 4.84  | 3.5 ± 0.65  | 72.8 ± 5.22 |
| CD70    | 0.84 ± 0.22  | 0.87 ± 0.27  | 0.79 ± 0.30  | 0.57 ± 0.15  | 0.14 ± 0.06 | 0.71 ± 0.20 |
| CD80    | 1.13 ± 0.34  | 1.66 ± 0.77  | 1.06 ± 0.60  | 1.44 ± 0.83  | 1.43 ± 0.07 | 1.53 ± 0.05 |
| CD86    | 0.75 ± 0.18  | 0.67 ± 0.31  | 0.76 ± 0.34  | 1.18 ± 0.44  | 2.34 ± 1.02 | 1.05 ± 0.84 |
| CD134   | 1.56 ± 0.60  | 1.30 ± 0.75  | 1.66 ± 0.59  | 1.58 ± 0.67  | 0.26 ± 0.10 | 0.13 ± 0.05 |
| CD154   | 0.42 ± 0.12  | 1.03 ± 0.33  | 2 ± 0.40     | 1.36 ± 0.33  | 0.45 ± 0.10 | 0.25 ± 0.10 |
| CD252   | 5 ± 1.06     | 4.65 ± 0.20  | 3 ± 0.57     | 4.60 ± 0.71  | 0.43 ± 0.15 | 0.52 ± 0.10 |

**Cell adhesion molecules**

| CD29    | 91 ± 4.80    | 89.60 ± 4.94 | 95 ± 1.38    | 97 ± 0.65    | 84 ± 3     | 89 ± 3.82 |
| CD31    | 1.2 ± 0.45   | 1.7 ± 0.64   | 1.3 ± 0.66   | 1.6 ± 0.93   | 0.26 ± 0.11 | 0.31 ± 0.13 |
| CD44    | 92.83 ± 1.64 | 93.60 ± 2.26 | 95.50 ± 6.23 | 89.60 ± 3.89 | 57.43 ± 2.40 | 53.75 ± 4.53 |
| CD49e   | 82 ± 5.43    | 89.75 ± 3.87 | 92.98 ± 3.45 | 97.23 ± 0.51 | 38.75 ± 7.22 | 34.33 ± 5.29 |
| CD54    | 69 ± 5.53    | 97.80 ± 0.67 | 64.20 ± 5.85 | 88.80 ± 4.92 | 63.25 ± 9    | 85.50 ± 5.90 |
| CD58    | 3.12 ± 1.17  | 7.44 ± 2.74  | 2.68 ± 1.47  | 3.06 ± 1.42  | 0.80 ± 0.45  | 3.50 ± 0.65 |
| CD62e   | 1.96 ± 0.52  | 2.4 ± 0.98   | 1.56 ± 0.57  | 3.03 ± 1.63  | 0.2 ± 0.09   | 0.9 ± 0.42  |
| CD102   | 1 ± 0.25     | 0.98 ± 0.56  | 0.88 ± 0.30  | 1.40 ± 0.72  | 0.1 ± 0.04   | 0.1 ± 0.01  |
| CD106   | 8.08 ± 1.58  | 48.75 ± 5.54 | 1.09 ± 0.82  | 49.50 ± 5.10 | 0.43 ± 0.02  | 7.75 ± 4.70 |
| CD146   | 4.83 ± 1.51  | 3.64 ± 0.82  | 3.16 ± 0.60  | 4 ± 0.64     | 0.1 ± 0.033  | 0.04 ± 0.038 |
| CD166   | 25.60 ± 1.64 | 24.4 ± 1.31  | 26.83 ± 2.03 | 27.20 ± 3.71 | 30.93 ± 0.05 | 31.67 ± 3.50 |

**Immunoregulatory molecules**

| CD39    | 1.55 ± 0.54  | 1.48 ± 0.64  | 2.68 ± 1.29  | 2.52 ± 1.26  | 0.03 ± 0.02  | 0.09 ± 0.01 |
| CD73    | 88.8 ± 3.99   | 90 ± 2.33    | 71.8 ± 6.72  | 79.75 ± 5.79 | 2.01 ± 0.08  | 1.8 ± 0.52  |
| CD200   | 69.20 ± 2.96  | 60 ± 8.05    | 2.43 ± 1.19  | 1.86 ± 1.05  | 0.14 ± 0.08  | 0.61 ± 0.47 |
| CD274   | 1.50 ± 0.35   | 82.40 ± 5.94 | 0.76 ± 0.13  | 64.80 ± 2.26 | 0.60 ± 0.34  | 66.25 ± 2.98 |
| HO-1    | 65.83 ± 2.21  | 66.25 ± 3.10 | 61.83 ± 4.78 | 68.60 ± 4.22 | 32.55 ± 5.10 | 35.66 ± 2.02 |

**Table 2**: Expression levels of different molecules present on undifferentiated and differentiated ADHLS as well as hepatocytes being cultivated in the presence or absence of inflammation cocktail. The data are presented as the mean ± SEM (standard error of the mean) percentage of each marker expression.
significantly impact its expression in differentiated ADHLSCs (28.66 ± 3.47%). Endothelial CD34 and embryonic SSEA4 markers were minimally expressed in the three tested cell types (undifferentiated and differentiated ADHLSCs as well as hepatocytes) without being influenced by inflammation priming.

Comparably to their minimal expression profiles observed in hepatocytes, the cell surface receptors CD45, CD95, CD184, CD106, CD146, and CD166 markers. All exhibited some expression in differentiated ADHLSCs, and hepatocytes. For instance, CD29 and CD44 expression was increased following inflammation priming (49,50 ± 5,10%) but to a lesser extent in hepatocytes (7,75 ± 4,70%).

As NK cells play a critical role in liver pathology, we determined the expression of the major activating ligands of NK cytolitic activity. The expression pattern of the NK ligands CD112, CD155, and ULBP-3 showed no significant alterations following hepatogenic differentiation or inflammation priming. For instance, the high and comparable CD112 and CD155 expression levels exhibited in undifferentiated ADHLSCs (50 ± 5,82% for CD112; 71,60 ± 4,32% for CD155) and differentiated ADHLSC (46,08 ± 3,35 for CD112; 72,80 ± 4,41 for CD155) were not modulated after inflammation priming of either undifferentiated ADHLSCs (58,75 ± 4,78% for CD112; 70,50 ± 6,55% for CD155) as well as differentiated ADHLSCs (43,60 ± 5,22% for CD112; 74 ± 5,82% for CD155). This maintained expression was also noticed in hepatocytes (23,5 ± 1,55% for CD112; 33,75 ± 2,43% for CD155) versus inflammation-primed hepatocytes (25,55 ± 1,93% for CD112; 37,25 ± 3,01% for CD155). On the other hand, ULBP-3 was minimally expressed in all these three cell types without being influenced by inflammation.

Immune regulation and its underlying mechanisms are an important component of liver immunity. The immune-regulatory molecules CD39 and CD274 were constitutively negative in all cell types whereas only CD274 was strongly upregulated after inflammation priming of undifferentiated ADHLSCs (82 ± 5,43% as well as in differentiated ADHLSCs (92,98 ± 3,45%) as compared to that in hepatocytes (38,75 ± 7,22%). However, inflammation priming did not exert any striking effect on this integrin expression level in all analyzed cell types. CD54 or intercellular adhesion molecule-1 (ICAM-1) expression was comparable in undifferentiated ADHLSCs (69 ± 5,53%), differentiated ADHLSCs (64,20 ± 5,85%), and hepatocytes (63,25 ± 9%).

| NK ligands | Undifferentiated | ADHLSCs | Differentiated | Hepatocytes |
|------------|-----------------|---------|----------------|-------------|
|            | Constitutive    | Priming | Constitutive    | Priming     | Constitutive | Priming     |
| CD112      | 50 ± 5,82       | 58,75 ± 4,30 | 46,08 ± 3,35    | 43,60 ± 5,24 | 23,5 ± 1,55  | 25,55 ± 1,93 |
| CD155      | 71,60 ± 4,32    | 70,50 ± 6,23 | 72,80 ± 4,41    | 74 ± 6,55   | 33,75 ± 2,43 | 37,25 ± 3,01 |
| ULBP-3     | 1,07 ± 0,26     | 1,46 ± 0,42 | 0,72 ± 0,16     | 1,20 ± 0,52  | 0,53 ± 0,25  | 1 ± 0,21     |

Constitutive Priming Constitutive Priming Constitutive Priming Constitutive Priming

Table 2: Continued.
On the other hand, although HO-1 was substantially and similarly expressed in hepatocytes (32.55 ± 5.10%) and inflammation-primed hepatocytes (35.66 ± 2.02%), CD73 showed only minimal expression under these conditions. Intriguingly, CD200 being highly expressed in undifferentiated ADHLSCs (69.20 ± 2.96%) was dramatically downregulated following hepatogenic differentiation (2.43 ± 1.19%). Similarly, its expression was very low in mature hepatocytes (0.14 ± 0.08%). In all these experimental cell groups, inflammation priming has any significant impact on CD200 protein expression level.

### 3.2. Modulation of CD200 Expression following Hepatogenic Differentiation

Firstly, quantitative real-time PCR (RT-qPCR) was carried out to estimate the CD200 mRNA level in naïve ADHLSC (expansion culture conditions) and hepatocytes. In agreement with flow cytometry results, RT-qPCR analysis revealed that CD200 transcript expression was extremely low in hepatocytes (Figure 2(a)). This observation is also confirmed by using western blotting (Figure 2(b)). CD200 protein expression in ADHLSC was also confirmed using immunofluorescence and is homogeneously distributed at the membrane level (Figure 2(c)).

Upon hepatogenic differentiation, we demonstrated that the CD200 mRNA expression level was clearly abolished in differentiated ADHLSCs as compared to undifferentiated cells (Figure 3(a)). Such CD200 downregulation is also observed in MSC from other tissues like the umbilical cord, bone marrow, and adipose tissue and submitted to the same hepatogenic differentiation protocol. Western blot analysis was performed to further assess, at the protein level, the alteration of CD200 expression noticed following hepatogenic differentiation. Consistently with flow cytometry results, CD200 protein expression level exhibited by the undifferentiated ADHLSCs is dramatically diminished after in vitro hepatogenic differentiation. The same results were obtained in both ADHLSCs and UCMSCs (Figure 3(b)).

During hepatogenic differentiation, the downregulation of CD200 looks to be dependent on culture steps. Given that the hepatogenic differentiation protocol is a multistep process, we investigated the kinetic of CD200 downregulation. Our data demonstrated that CD200-decreased mRNA expression happens starting from the first step (Figure 3(c)). Thereafter, we treated ADHLSC separately with each of the growth factors used in the cocktail of differentiation to gain insights regarding the potential signaling events behind the dramatic shutdown of CD200 expression following hepatogenic differentiation. As shown in Figure 3(d), data presented as a relative CD200 mRNA level in treated versus untreated ADHLSC (serum-free conditions) clearly shows that HFG and bFGF exerted no effect and a slightly nonsignificant effect, respectively. Nevertheless, both EGF and OSM treatments resulted in a significant decrease of about half of the CD200 mRNA level. Such diminution is in line with the decreased CD200 mRNA levels observed after the first and the last steps of the hepatogenic differentiation protocol.

Finally, we checked if CD200 mRNA expression was also modulated after inflammation priming. As shown in Figure 4, this parameter was investigated in undifferentiated and differentiated ADHLSCs as well as in hepatocytes. Whilst no effect was observed in ADHLSCs (Figure 4(a)), inflammation priming of hepatocytes strongly induced the CD200 mRNA level (Figure 4(b)).

The functional network of CD200 and its interacting proteins was analyzed to better highlight which pathways might be altered during hepatogenic differentiation. Due to its great immunological importance, CD200 protein network was analyzed by using STRING version10 database. This analysis was selected for its many advantages among which extensive collection of precomputed interaction data derived from various sources, such as, high-throughput experimental data, literature data, and computational predictions. This tool was used to query, retrieve, and analyze the CD200 protein interaction network with the interactions restricted to those available for Homo sapiens. Using CD200 as a query, and choosing the prediction methods to include neighborhood, gene fusion, co-occurrence, coexpression, experiments, databases, and text mining, a network of eleven interacting proteins was constructed (Figure 5). This interaction network is visualized in the form of a graph with the protein molecules forming the nodes of the graph and the interactions forming the edges. Among those eleven predicted interacting proteins, four were already confirmed to interact with CD200 among which three (CD200R1, HCRTR2, and CD200R1L) were experimentally determined, and one (CD200R1) was determined from a curated database whilst the remaining seven were predicted based on text mining and were verified using PubMed literature database. Indeed, CD200R1 and CD200R1L (CD200R2) are receptors for CD200 whilst HCRTR2 is a hypocretin (orexin) receptor 2 implicated in neuropeptide signaling pathway [7]. Orexins and orexin receptors, a family of hypothalamic neuropeptides and G protein-coupled receptors are involved in the regulation of feeding behavior [7] in addition to their ability to trigger phospholipase C signaling via activating Ca²⁺ influx [8].

### 4. Discussion

By maintaining vital metabolic homeostasis, good functioning of the liver is essential for survival. Due to its high ability to regenerate and to its continuous extrahepatic cellular supply, cell therapy is currently appreciating the potential of exogenous cell suspensions in replenishing the liver and correcting its functional and/or structural defects. Extensive preclinical work has been conducted to study the mechanistic pathways that govern genesis of the major liver cells, hepatocytes. Nowadays, different stem cells are being investigated to hopefully increase the diversity of cell pools and availability of cell-based therapy products for patients who can no longer regenerate their altered hepatic tissue [9]. In addition to adult bone marrow-derived and embryonic stem cells that have been well described for their potential to transdifferentiate into mature hepatocyte-like cells [9], ADHLSCs have recently emerged as a novel progenitor reservoir of hepatocytes [2, 4, 10]. ADHLSC in vitro and in vivo hepaticotopic differentiation potential [2, 4] and hypomunogenic profile [5] support their usefulness for liver regeneration [2-5, 10].
Acceptance of engrafted ADHLSCs could be a result of the surrounding inflammatory condition sensing as well as the modulation of the host immune responses like to what has been reported for other MSCs [11, 12]. Based on the interesting expression and secretion profiles of naïve ADHLSC [3], the current study aimed at appreciating the impact of hepatic differentiation and inflammation on those features. In agreement with our recent observations [5], we confirmed that ADHLSCs are negative for CD34 and SSEA-4 but positive for CD90 and CD105 with no influence of inflammation and differentiation on that expression profile. Of note, CD90, which is absent in mature hepatocytes, remains expressed in differentiated ADHLSCs. This constitutive CD90 expression could be advantageous since decreased expression of CD90 has been reported to impair MSC immunosuppressive capacity [13].

Consistent with the previously reported ADHLSCs’ hypoimmunogenicity [2, 5], we observed that, regardless of inflammation priming, undifferentiated and differentiated ADHLSCs as well as hepatocytes are negative for HLA-DR, HLA-G, and the costimulatory molecules CD27, CD70, CD80, CD86, CD134, CD154, and CD252 but positive for

---

**Figure 2:** CD200 expression in naïve ADHLSC and mature nonplated hepatocytes. (a) Total RNA extracted from both naïve ADHLSCs and nonplated hepatocytes was retrotranscribed, the cDNA-synthesized and PP/IA-normalized CD200 mRNA levels were evaluated by RT-qPCR. A very significant low level of this marker is noticed in mature hepatocytes (n = 4) (**p < 0.001 versus naïve ADHLSC, unpaired t-test). (b) Cell extracts were prepared and immunoblotted with anti-CD200 and anti-GAPDH antibodies as described in Materials and Methods. Low CD200 protein expression in mature hepatocytes (n = 3) is correlated to mRNA expression as compared to ADHLSC. Ponceau S staining shows the quality and the quantity of loading. (c) Immunofluorescence on fixed naïve ADHLSCs was also performed to appreciate the CD200 protein expression. CD200-positive immunoreactivity was significantly confirmed. The lower picture shows that no immunofluorescence signal was observed when cells were incubated with only secondary antibody. Pictures from 3 different donors were taken at a magnification of 200x.
Figure 3: Downregulation of CD200 expression after in vitro hepatogenic differentiation of ADHLSC. ADHLSCs were submitted to an in vitro hepatogenic differentiation protocol and processed for CD200 expression analysis. (a) Total RNA extracted from both undifferentiated and differentiated MSCs (the umbilical cord MSC (UCMSC), bone marrow MSC (BM-MSC), and adipose tissue MSC (AT-MSC)) was retrotranscribed, the cDNA synthesized, and RT-qPCR applied for CD200 gene marker. Hepatogenic differentiation was correlated with a strong downregulation of this marker. (b) Total proteins extracted from differentiated and undifferentiated ADHLSCs and UCMSC were analyzed using western blotting. Hepatogenic differentiation was associated with a significant decrease of CD200 protein expression. (c) Downregulation of CD200 mRNA occurs early at the first step of the hepatogenic differentiation protocol as demonstrated using RT-qPCR. (d) Downregulation of CD200 expression in differentiated ADHLSCs occurs under EGF and oncostatin M treatment. ADHLSCs were treated with one or the other growth factor/cytokine used in the hepatogenic differentiation protocol (epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), or oncostatin M (OSM)). Cells were treated for 3 days using the same basal medium as for differentiation experiments and under serum-free conditions. Total RNA for each group was extracted and retrotranscribed for CD200 mRNA analysis using RT-qPCR. Data shown represent the mean ± SEM of three different experiments as indicated in the graph (\( ^{\ast} p < 0.05; \ ^{\ast\ast} p < 0.01 \) versus corresponding untreated cells, unpaired t-test).
HLA-ABC molecules. The absence of CD134 and CD252 in differentiated ADHLSCs as well as hepatocytes are grown under basic or inflammatory-priming conditions. Total RNA was isolated and PPIA-normalized CD200 mRNA levels were quantified by RT-qPCR. Data shown represent the mean ± SEM of three different experiments (*p < 0.05; **p < 0.01 versus corresponding untreated cells, unpaired t-test; ***p < 0.001 versus corresponding treated undifferentiated cells, one-way ANOVA followed by the Tukey post hoc test).

**Figure 4:** CD200 mRNA expression after inflammation priming. Undifferentiated ADHLSCs, (a) differentiated ADHLSCs as well as (b) hepatocytes were grown under basic or inflammatory-priming conditions. Total RNA was isolated and PPIA-normalized CD200 mRNA levels were quantified by RT-qPCR. Data shown represent the mean ± SEM of three different experiments (*p < 0.05; **p < 0.01 versus corresponding untreated cells, unpaired t-test; ***p < 0.001 versus corresponding treated undifferentiated cells, one-way ANOVA followed by the Tukey post hoc test).

**Figure 5:** STRING database-generated protein interaction network generated using CD200 protein name as query. The blue and pink colours correspond to known interactions from curated and experimental work, respectively, whilst the light-green colour corresponds to interaction prediction based on text mining.
poorly characterized but described to be involved in angiogenesis) [26]. However, all cells are positive to CD29 (essential for hepatocyte survival) [27], CD49e, and CD166 (playing an antiapoptotic role for liver cells) [28] regardless of presence or absence of inflammatory signals. Our observations for CD102, CD146, and CD166 expression levels in undifferentiated ADHLSCs are in line with our previous observations [5], CD44 (involved in regulating liver inflammation) [29] and CD54 (involved in the recruitment of hepatic-natural killer cells in the liver) [30] exhibit high levels in undifferentiated and differentiated ADHLSCs as well as hepatocytes. Inflammatory signals reinforce CD54 expression in these different cells and increase CD44 expression only in differentiated ADHLSCs. Remarkably, the minimal CD106 expression (involved in enabling neutrophil migration within the liver) [31] exhibited by both undifferentiated and differentiated ADHLSCs was strongly induced by inflammatory signals to levels higher than those exhibited by inflammation-primed hepatocytes. These observations indicate that the different examined CAMs are heterogeneously expressed in the different tested cell types and exhibit different sensitivities to inflammation.

As a key component of the liver’s innate immunity, NK cells are primarily involved in host defense but also have regulatory effects during their interactions with other types of liver cells [32]. Regardless of inflammation priming, both differentiated ADHLSCs and hepatocytes were positive for CD112 and CD155 but negative for ULBP-3, in a manner comparable to that exhibited by undifferentiated ADHLSCs. NK cells’ lytic activity could be triggered upon interaction of CD112 or CD155 with the same NK-activating receptor DNAM-1 [33] or ULBP-3 with NKG2D receptor [34]. Although the absence of ULBP-3 seems advantageous, the presence of CD112 and CD155 might be risky in terms of allowing NK-mediated lysis of those liver-derived cells.

Given that ADHLSCs could exhibit immunomodulatory properties, it was then important to evaluate the expression and modulation of several relevant immune regulatory molecules. Undifferentiated and differentiated ADHLSCs were positive for CD73 and HO-1 but negative for CD274, regardless of CD39, of inflammation priming. Interestingly, although initially negative for CD274, inflammation strikingly increased its expression on all the studied cells. CD274 expression is known to be upregulated in response to proinflammatory cytokines where it exerts an inhibitory role on the costimulatory pathway of T cells [35]. CD274 upregulation could then compensate the effect of upregulated CD40 expression observed after inflammation priming, thus inhibiting T cell activation.

A major output of this study is the downregulation of CD200 expression that takes place during hepatogenic differentiation. This impaired CD200 expression in differentiated ADHLSCs is consistent with the absence of CD200 expression in hepatocytes. CD200 is a transmembrane surface glycoprotein which, upon engagement with its receptor (CD200R), delivers inhibitory signals leading to immunosuppression, inhibition of inflammation, and tolerance to allografts [33]. Given the important inflammation-inhibitory potential of CD200, the observed loss of its expression in differentiated ADHLSCs could limit their anti-inflammatory capacity, thus imposing undesired consequences during the application of ADHLSC-based liver therapy. CD200 is widely expressed in many cell types, among which are extrahepatic MSCs. This expression is uneven and can be modulated depending on the tissue origin and growth conditions. For instance, CD200 expression is not equal in the bone marrow, umbilical cord blood, Wharton’s jelly, and adipose tissue-derived MSCs [36, 37]. Of great importance, hepatic progenitor cells (HPCs) isolated from the adult human liver are highly similar to cultured primary hepatocytes in their transcriptional profiles where both cell types are negative for CD200 expression [16]. Expression of several MSC markers including CD73, CD146, and CD200 is downregulated after adipogenic and osteogenic differentiation [38] whilst only CD200 expression is completely abolished following chondrogenic differentiation [38]. Identifying specific markers to evaluate the multilineage differentiation potential of stem cells is thus highly important for the improvement of stem-cell-based therapies. CD105 expression was demonstrated to be significantly downregulated following adipogenic, chondrogenic, and osteogenic differentiation of umbilical cord blood MSCs [39]. In addition, to be used as a specific marker for a determined cell population or for a defined cell differentiation status, the observations made in this study might suggest CD200 as a marker for the immunomodulatory potential of ADHLSCs.

Protein-protein interaction (PPI) network revealed that several proteins may interact with CD200. These proteins may be expressed by different liver-derived cells and may also have implications in various cell biology features such as for roundabout, axon guidance receptor, homolog 4 (Robo4) in cell migration and angiogenesis during endothelial inflammatory responses [40, 41], and insulin receptor substrate 1 (IRS-1) that may mediate the control of various cellular processes related to insulin and insulin-like growth factor-1 (IGF-1) receptors [42]. Following the engagement of CD200 with CD200 receptor 1, the tumor necrosis factor receptor superfamily member 11a (TNFRSF11A) can interact with the TNF receptor-associated factors (TRAFs) [43] which modulate the immune and inflammatory responses particularly during the interaction between T cells and dendritic cells [43]. The potential interaction of CD200 with translocator protein (TSPO) could have important consequences for ADHLSC therapeutic applications because of its involvement in the regulation of cellular metabolic energy. TSPO, a mitochondrial outer membrane protein that belongs to a family of tryptophan-rich sensory, modulates critical biological functions, such as cellular bioenergetics and metabolism, immunomodulation, and apoptosis [44]. The juxtaposition of TSPO at the cytosolic/mitochondrial interface and the existence of endogenous ligands that are regulated by metabolism suggest that TSPO functions to adapt mitochondrial to cellular metabolism [45]. Indeed, TSPO has been shown to affect mitochondrial energy homeostasis through modulation of fatty acid oxidation (FAO). Such function positively correlates with high levels of TSPO expression as observed in cell types active in lipid storage/metabolism [46]. From a pharmacological perspective, the specific upregulation of TSPO in
inflammatory and injury conditions makes TSPO an interesting, druggable target of mitochondrial metabolism [47].

The potential interactions of CD200 with Numb, a cell fate determinant with a critical role in the regulation of pluripotency and stem cell division [48], are of importance. Indeed, Numb phosphorylation by pluripotency-associated transcription factor NANOG and subsequent p53 degradation drive self-renewability and proliferation of tumor-initiating cells, which results in higher liver oncogenesis [49]. Second, Numb inhibits the Notch pathway, a crucial regulator of stem cell behavior [50]. Several mechanisms of actions are proposed [50] including the ubiquitination of Notch1 receptor and the subsequent degradation of the Notch intracellular domain following receptor activation [51] and the inhibition of Notch endosomal trafficking and recycling [52]. In the context of ADHLSC cell therapy, CD200 and Numb interactions could play a crucial role to maintain the proper homeostasis of both undifferentiated and differentiated cells.

In conclusion, we suggest that the modulation of the CD200 pathway might be involved in the control of the differentiated ADHLSC immunosuppressive function. Whilst requiring further investigations, the current data are helpful for tackling the interest of deeply exploring the immune biology of liver cells to transplant for an efficient management of liver diseases by cell therapy-based approaches. Thanks to their ability to functionally differentiate into hepatocyte-like cells and to maintain the major immunological profile of mature hepatocytes, differentiated ADHLSCs might support their development for liver cell therapy.

Abbreviations

ADHLSC: Adult-derived human liver stem/progenitor cells
bFGF: Basic fibroblast growth factor
EGF: Epidermal growth factor
HGF: Hepatocyte growth factor
NK: Natural killer
OSM: Oncostatin M.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Mustapha Najimi and Mehdi Najar contributed equally to this work.

Acknowledgments

This project was supported by BRUSTEM, an impulse program of the Institute for the encouragement of Scientific Research and Innovation of Brussels (ISRIB). Hoda El-Kehdy is a postdoc grant holder from IREC (Institut de Recherche Expérimentale et Clinique). Mustapha Najimi is a Principal Investigator of IREC. Mehdi Najar is a Belgian Fonds National de la Recherche Scientifique (FNRS) postdoctoral researcher.

References

[1] S. J. Forbes, S. Gupta, and A. Dhawan, "Cell therapy for liver disease: from liver transplantation to cell factory," *Journal of Hepatology*, vol. 62, no. 1, pp. S157–S169, 2015.
[2] M. Najimi, D. N. Khuu, P. A. Lysy et al., "Adult-derived human liver mesenchymal-like cells as a potential progenitor reservoir of hepatocytes?" *Cell Transplantation*, vol. 16, no. 7, pp. 717–728, 2007.
[3] S. Berardis, C. Lombard, J. Evraerts et al., "Gene expression profiling and secretome analysis differentiate adult-derived human liver stem/progenitor cells and human hepatic stellate cells," *PLoS One*, vol. 9, no. 1, article e86137, 2014.
[4] D. N. Khuu, I. Scheers, S. Ehnhert et al., "In vitro differentiated adult human liver progenitor cells display mature hepatic metabolic functions: a potential tool for in vitro pharmacotoxicological testing," *Cell Transplantation*, vol. 20, no. 2, pp. 287–302, 2011.
[5] G. Raicevic, M. Najar, M. Najimi et al., "Influence of inflammation on the immunological profile of adult-derived human liver mesenchymal stromal cells and stellate cells," *Cytotherapy*, vol. 17, no. 2, pp. 174–185, 2015.
[6] D. Szklarczyk, A. Franceschini, M. Kuhn et al., "The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored," *Nucleic Acids Research*, vol. 39, supplement 1, pp. D561–D568, 2011.
[7] T. Sakurai, "Orexin and orexin receptors," in *In Hypocretins: Integrators of Physiological Functions, de Lecca, L. and Satchiffe, J. G.*, Eds., pp. 13–23, Springer, New York, 2005.
[8] P. E. Lund, R. Shariatmadari, A. Uustare et al., "The orexin OX1 receptor activates a novel Ca2+ influx pathway necessary for coupling to phospholipase C," *The Journal of Biological Chemistry*, vol. 275, no. 40, pp. 30806–30812, 2000.
[9] S. Y. Lee, H. I. Kim, and D. Choi, "Cell sources, liver support systems and liver tissue engineering: alternatives to liver transplantation," *International Journal of Stem Cells*, vol. 8, no. 1, pp. 36–47, 2015.
[10] D. N. Khuu, O. Nyabi, C. Maerckx, E. Sokal, and M. Najimi, "Adult human liver mesenchymal stem/progenitor cells participate in mouse liver regeneration after hepatectomy," *Cell Transplantation*, vol. 22, no. 8, pp. 1369–1380, 2013.
[11] S. Pluchino and C. Cossetti, "How stem cells speak with host immune cells in inflammatory brain diseases," *Glia*, vol. 61, no. 9, pp. 1379–1401, 2013.
[12] Y. Wang, X. Chen, W. Cao, and Y. Shi, "Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications," *Nature Immunology*, vol. 15, no. 11, pp. 1099–1106, 2014.
[13] D. Campioni, R. Rizzo, M. Stignani et al., "A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs," *Cytometry. Part B. Clinical Cytometry*, vol. 76, no. 3, pp. 225–230, 2009.
[14] M. D. Vu, X. Xiao, W. Gao et al., "OX40 costimulation turns off Foxp3+ Tregs," *Blood*, vol. 110, no. 7, pp. 2501–2510, 2007.
[15] A. Nasef, N. Mathieu, A. Chapel et al., "Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G," *Transplantation*, vol. 84, no. 2, pp. 231–237, 2007.
[16] J. Li, J. Xin, L. Zhang et al., "Human hepatic progenitor cells express hematopoietic cell markers CD45 and CD109,"
International Journal of Medical Sciences, vol. 11, no. 1, pp. 65–79, 2014.

[17] H. Malhi, G. J. Gores, and J. J. Lemasters, “Apoptosis and necrosis in the liver: a tale of two deaths?” Hepatology, vol. 43, no. S1, pp. 31–44, 2006.

[18] N. Hao, C. Li, M. Liu et al., “SDF-1/CXCR4 axis promotes MSCs to repair liver injury partially through trans-differentiation and fusion with hepatocytes,” Stem Cells International, vol. 2015, Article ID 960387, p. 10, 2015.

[19] E. P. Chan and R. G. Wells, “Today’s hepatic stellate cells: not your father’s Sternzellen,” Hepatology, vol. 45, no. 5, pp. 1326–1327, 2007.

[20] X. Shen, F. Hong, V. A. Nguyen, and B. Gao, “IL-10 attenuates IFN-α-activated STAT1 in the liver: involvement of SOCS2 and SOCS3,” FEBS Letters, vol. 480, no. 2–3, pp. 132–136, 2000.

[21] H. Bouhila, R. Nyga, F. Cartier et al., “Molecular and functional characterisation of hepatic slam CD229 and ITS implication in the development of hepatocellular carcinoma,” Gut, vol. 60, Supplement 1, pp. A226–A227, 2011.

[22] P. B. Patil, M. Joshi, V. K. Kuna et al., “CD271 identifies functional human hepatic stellate cells, which localize in peri-sinusoidal and portal areas in liver after partial hepatectomy,” Cytotherapy, vol. 16, no. 7, pp. 990–999, 2014.

[23] I. A. Malik, I. Stange, G. Martius et al., “Role of PECAM-1 in radiation-induced liver inflammation,” Journal of Cellular and Molecular Medicine, vol. 19, no. 10, pp. 2441–2452, 2015.

[24] P. Wang, B. Qi, P. Chen et al., “CD85 expression of liver tissue in patients with chronic hepatitis B virus infection,” Chinese Medical Journal, vol. 121, no. 6, pp. 557–560, 2008.

[25] P. F. Lalar, P. Shields, A. Grant, and D. H. Adams, “Recruitment of lymphocytes to the human liver,” Immunology and Cell Biology, vol. 80, no. 1, pp. 52–64, 2002.

[26] C. Sers, G. Riethmüller, and J. P. Johnson, “MUC18, a melanoma-progression associated molecule, and its potential role in tumor vascularization and hematogenous spread,” Cancer Research, vol. 54, no. 21, pp. 5689–5694, 1994.

[27] G. G. M. Pinkse, M. P. Voorhoeve, M. Noteborn, O. T. Terpstra, C. Sers, G. Riethmüller, and J. P. Johnson, “Stem Cells International, vol. 2015, Article ID 960387, p. 10, 2015.”

[28] R. M. Gorczynski, “CD200:CD200R-mediated regulation of immunity,” ISRN Immunology, vol. 2012, Article ID 682168, pp. 1–18, 2012.

[29] A. R. Mistry and C. A. O’Callaghan, “Regulation of ligands for the activating receptor NKG2D,” Immunology, vol. 121, no. 4, pp. 439–447, 2007.

[30] H. Wiendl, M. Mitsdoerffer, D. Schneider et al., “Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies,” The FASEB Journal, vol. 17, no. 13, pp. 1892–1894, 2003.

[31] M. Pietilä, S. Lehtonen, E. Tuovinen et al., “CD200 positive human mesenchymal stem cells suppress TNF-alpha secretion from CD200 receptor positive macrophage-like cells,” PLoS One, vol. 7, no. 2, article e31671, 2012.

[32] M. Najari, G. Raicevic, F. Jebbawi et al., “Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes,” Immunology Letters, vol. 146, no. 1–2, pp. 50–56, 2012.

[33] B. Delorme, J. Ringe, N. Gallay et al., “Speciﬁc plasma membrane protein phenotype of culture-ampliﬁed and native human bone marrow mesenchymal stem cells,” Hematop Stem Cells, vol. 111, no. 5, pp. 2631–2635, 2008.

[34] H. J. Jin, S. K. Park, W. Oh, Y. S. Yang, S. W. Kim, and S. J. Choi, “Down-regulation of CD105 is associated with multi-lineage differentiation in human umbilical cord blood-derived mesenchymal stem cells,” Biochemical and Biophysical Research Communications, vol. 381, no. 4, pp. 676–681, 2009.

[35] S. Suchting, P. Heal, K. Tahtis, L. M. Stewart, and R. Bicknell, “Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration,” The FASEB Journal, vol. 19, no. 1, pp. 121–123, 2005.

[36] H. Zhao, A. R. Anand, and R. K. Ganju, “Slit2-Robo4 pathway modulates lipopolysaccharide-induced endothelial inﬂammation and its expression is dysregulated during endotoxemia,” Journal of Immunology, vol. 192, no. 1, pp. 385–393, 2014.

[37] K. Mardilovich, S. L. Pankratz, and L. M. Shaw, “Expression and function of the insulin receptor substrate proteins in cancer,” Cell Communication and Signaling: CCS, vol. 7, no. 1, p. 14, 2009.

[38] J. I. Inoue, T. Ishida, N. Tsukamoto et al., “Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling,” Experimental Cell Research, vol. 254, no. 1, pp. 14–24, 2000.

[39] G. J. Liu, R. J. Middleton, W. W. Kam et al., “Functional gains in energy and cell metabolism after TSPO gene insertion,” Cell Cycle, vol. 19, no. 5, pp. 436–447, 2017.

[40] P. Gut, “Targeting mitochondrial energy metabolism with TSPO ligands,” Biochemical Society Transactions, vol. 43, no. 4, pp. 537–542, 2015.

[41] L. N. Tu, A. H. Zhao, M. Hussein, D. M. Stocco, and V. Selvaraj, “Translocator protein (TSPO) affects mitochondrial fatty acid oxidation in steroidogenic cells,” Endocrinology, vol. 157, no. 3, pp. 1110–1121, 2016.

[42] M. M. Faraldo and M. A. Glukhova, “Regulating the regulator: Numb acts upstream of p53 to control mammary stem and progenitor cell,” The Journal of Cell Biology, vol. 211, no. 4, pp. 737–739, 2015.

[43] H. R. Siddique, D. E. Feldman, C. L. Chen, V. Punj, H. Tokumitsu, and K. Machida, “NUMB phosphorylation
destabilizes p53 and promotes self-renewal of tumor-initiating cells by a NANOG-dependent mechanism in liver cancer,” *Hepatology*, vol. 62, no. 5, pp. 1466–1479, 2015.

[49] J. Liu, C. Sato, M. Cerletti, and A. Wagers, “Notch signaling in the regulation of stem cell self-renewal and differentiation,” *Current Topics in Developmental Biology*, vol. 92, pp. 367–409, 2010.

[50] V. Kandachar and F. Roegiers, “Endocytosis and control of Notch signaling,” *Current Opinion in Cell Biology*, vol. 24, no. 4, pp. 534–540, 2012.

[51] M. A. McGill and C. J. McGlade, “Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain,” *The Journal of Biological Chemistry*, vol. 278, no. 25, pp. 23196–23203, 2003.

[52] L. Couturier, K. Mazouni, and F. Schweisguth, “Inhibition of Notch recycling by Numb: relevance and mechanism(s),” *Cell Cycle*, vol. 12, no. 11, pp. 1647–1648, 2013.